Properties of recombinant hepatitis B vaccine.
A large-scale purification method for hepatitis B surface antigen produced in a recombinant yeast (Saccharomyces cerevisiae) was established. The resulting HBsAg was greater than 99% pure and suitable for vaccine use. The yeast-derived HBsAg was structurally and biochemically similar to plasma-derived HBsAg. The anti-HBs antibody producing potency of the yeast-derived vaccine in mice was significantly higher than that of the plasma-derived vaccine. The yeast-derived vaccine induced protective antibody against hepatitis B virus of either adr or ayw subtype in a chimpanzee efficacy study. These observations demonstrate the usefulness of the yeast-derived vaccine as a second-generation hepatitis B vaccine.
D000596:Amino Acids / Q000032:analysis; D000818:Animals; D000941:Antigens / Q000276:immunology; D005069:Evaluation Studies as Topic; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000276:immunology* / Q000302:isolation & purification; D017325:Hepatitis B Vaccines; D007114:Immunization; D051379:Mice; D002679:Pan troglodytes; D011993:Recombinant Fusion Proteins / Q000276:immunology* / Q000302:isolation & purification; D011994:Recombinant Proteins / Q000276:immunology*; D012441:Saccharomyces cerevisiae / Q000235:genetics; D014614:Vaccines, Synthetic / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000276:immunology
D000596:Amino Acids; D000941:Antigens; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines